not yet recruiting: Integrated Molecular Profiling in Advanced Cancers Trial - breast, non-small cell lung, colorectal, ovarian, phase 1 (patients) - Full Text View - ClinicalTrials.gov UHN (Toronto)

 Advanced cancer

Advanced breast, non-small cell lung, colorectal and ovarian cancers; as well as patients who are phase I trial candidates

 

Purpose

Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.

Biomarkers are specific characteristics of the cancer that may help provide prognostic information (i.e. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.

The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, in order to help their physicians to identify which clinical trials of molecularly targeted therapies may be most appropriate for the patient in the future.

Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT)

This study is not yet open for participant recruitment.

Verified on January 2012 by University Health Network, Toronto

First Received on January 4, 2012.   Last Updated on January 5, 2012   History of Changes

Sponsor:	University Health Network, Toronto
Collaborator:	Princess Margaret Hospital, Canada
Information provided by (Responsible Party):	University Health Network, Toronto
ClinicalTrials.gov Identifier:	NCT01505400